



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** pNL4-3.HSA.R-

**Catalog Number:** 3421

**Lot Number:** 110077

**Release Category:** C

**Provided:** 5 µg of dried purified DNA stabilized in DNastable *PLUS*

**Cloning Vector:** pUC-19  
Ampicillin resistant

**Description:** Replication competent proviral DNA. Vpr- due to a frameshift at Vpr aa 26.

**Special Characteristics:** This construct is 14,975 bp including the insert.  
Murine heat stable antigen CD24 (HSA) gene was inserted into the pNL4-3 nef gene to produce this clone. Virus can be produced by transfecting  $2 \times 10^6$  293 or 293T cells with 20 µg NL4-3 DNA. Transfections can be performed in a 10 cm<sup>2</sup> tissue culture dish using standard calcium phosphate protocols. Virus is typically harvested 48 hours post-transfection. Infections should be performed in a total volume of 0.5 ml. The amphotropic pseudotypes generally have much higher infectivity than those bearing HIV-1 env. Cultures infected with HSA viruses can be assayed by FACS analysis with a commercial CD24 antibody (PharMingen) 2-5 days post-infection.

[Contributor provided plasmid map](#)

[Plasmid map and sequence file lot 110077](#)

This reagent is currently being provided as dried purified DNA stabilized in DNastable *PLUS*. Please see the notice for additional information and the protocol for reconstitution of dried DNA reagents. [Dried DNA Notice](#)

**Recommended Storage:** Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier bag.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Contributor:** Dr. Nathaniel Landau, Aaron Diamond AIDS Research Center, The Rockefeller University.

**References:** He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. *J Virol* **69**:6705-6711, 1995.

Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. *Virology* **206**:935-944, 1995.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3.HSA.R- from Dr. Nathaniel Landau." Also include the references cited above in any publications.

**Patent pending. Requests from commercial organizations must be directed to the New York University Office of Industrial Liaison at the following email address: [sadhana.chitale@nyumc.org](mailto:sadhana.chitale@nyumc.org).**

**Last Updated** March 19, 2018

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.